Greater Glasgow and Clyde Medicines

Formulary Search Results for: INSULIN GLARGINE

6.1.1.2 Intermediate- and long-acting insulins - View Category

Total Formulary
INSULIN GLARGINE

Restrictions:

Restricted to patients with type 1 diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

Prescribing Notes:

It is good practice to prescribe biosimilar insulins by brand name.   The current preferred brand in NHSGGC is Semglee®

Please note: Insulin glargine is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received. 

Insulin glargine 300 units/ml (Toujeo®) is further restricted to use in patients where the use of high-strength insulin is appropriate.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Preferred List
BIPHASIC INSULIN ASPART (NOVOMIX 30)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Total Formulary
INSULIN DEGLUDEC (TRESIBA)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.  Restricted to use in accordance with local guidance which includes information on preferred alternative options.

Prescribing Notes:

Note: Insulin degludec is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Preferred List
BIPHASIC ISOPHANE INSULIN (HUMULIN M3)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Total Formulary
INSULIN DETEMIR (LEVEMIR)

Restrictions:

Insulin detemir (Levemir®) is restricted to use in adults with severe/ frequent nocturnal hypoglycaemia. Not for routine use in type 2 diabetes unless patients suffers from recurrent episodes of hypoglycaemia.  Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Preferred List
ISOPHANE INSULIN (HUMULIN I, INSULATARD)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

BNF Link

6.1.1.2 Intermediate- and long-acting insulins - View Category

Total Formulary
BIPHASIC INSULIN LISPRO (HUMALOG MIX 25, HUMALOG MIX 50)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

BNF Link

6.1.1.1 Short-acting insulins - View Category

Preferred List
INSULIN ASPART

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

Prescribing Notes:

Insulin aspart preparations may differ in terms of speed of onset of action and should therefore be prescribed by brand name.

Different devices and presentations for administration of the same insulin may differ in cost.  When prescribing for the 1st time, use the most cost-effective device that best meets the patient's needs.

BNF Link

6.1.1.1 Short-acting insulins - View Category

Total Formulary
INSULIN GLULISINE (APIDRA) (injection)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes and for use in patients where regular human soluble insulin is inappropriate.

BNF Link

6.1.1.1 Short-acting insulins - View Category

Preferred List
INSULIN LISPRO (HUMALOG) (injection)

Restrictions:

Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.

Prescribing Notes:

Currently, only the 100 units/ml preparations have been considered and added to Formulary. Other strengths are currently non-Formulary

BNF Link